Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, ...
Envudeucitinib is a precision-designed, oral small molecule inhibitor of tyrosine kinase 2 (TYK2), currently in late-stage clinical development for the treatment of moderate-to-severe plaque psoriasis and systemic lupus erythematosus (SLE). It aims to offer high efficacy and a favorable safety profile compared to existing systemic therapies.
Price Range: N/A (Clinical stage, not yet commercialized)
Pain Points: Addressing the need for effective, convenient, and safe oral systemic treatments for chronic autoimmune skin and systemic diseases, reducing reliance on injections or less specific broad-spectrum immunosuppressants.
Solutions: Early and robust improvements in skin clearance, quality of life, and symptom management for patients suffering from plaque psoriasis and SLE.
Target Users: Healthcare providers (dermatologists and rheumatologists) and patients diagnosed with moderate-to-severe plaque psoriasis or systemic lupus erythematosus.
A-005 is an internally discovered, central nervous system (CNS)-penetrant allosteric inhibitor of TYK2. It is currently in Phase 1 clinical development, specifically engineered to cross the blood-brain barrier to modulate neuroinflammation, which is a key driver in various neurodegenerative and neuroinflammatory conditions.
Price Range: N/A (Clinical stage)
Pain Points: Limited treatment options for diseases involving neuroinflammation and the difficulty of delivering drugs effectively into the central nervous system.
Solutions: Precision targeting of the TYK2 pathway within the brain to mitigate neuroinflammatory cascades.
Target Users: Neurologists and patients suffering from neuroinflammatory or neurodegenerative disorders.
Supply Chain
Contract Research Organizations (CROs)Specialized chemical manufacturing facilitiesClinical trial logistics providers
Lonigutamab is a monoclonal antibody that targets the insulin-like growth factor 1 receptor (IGF-1R), developed as a subcutaneous therapy for thyroid eye disease (TED). It is designed to provide clinical benefits while potentially improving upon the administration methods of current standards of care.
Price Range: N/A (Clinical stage)
Pain Points: The need for effective disease-modifying therapies for TED that offer improved patient convenience through subcutaneous delivery.
Solutions: Blocking IGF-1R to reduce the pro-inflammatory and fibrotic processes that lead to the characteristic eye-bulging and inflammation associated with TED.
Target Users: Ophthalmologists, endocrinologists, and patients diagnosed with moderate-to-severe thyroid eye disease.
Contract Manufacturing Organizations (CDMOs) - API Drug SubstanceContract Manufacturing Organizations (CDMOs) - Drug ProductContract Research Organizations (CROs)Raw Material & Reagent SuppliersSpecialty Chemical & Intermediate Suppliers
Downstream
3
Kaken Pharmaceutical Co., Ltd.TSE:4521Patients / Prescribers (Future End Market)Foresite Labs
